Copland, Mhairi

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

Copland, M., Hamilton, A., Elrick, L. J., Baird, J. W., Allan, E. K., Jordanides, N., Barow, M., Mountford, J. C., & Holyoake, T. L. (2006) · Blood

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 635

Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells

Abraham, S. A., Hopcroft, L. E. M., Carrick, E., Drotar, M. E., Dunn, K., Williamson, A. J. K., Korfi, K., Baquero, P., Park, L. E., Scott, M. T., et al. (2016) · Nature

Chronic Myeloid Leukemia TreatmentsAcute Myeloid Leukemia Research

Cited by 225

De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial

Clark, R. E., Polydoros, F., Apperley, J. F., Milojkovic, D., Rothwell, K., Pocock, C., Byrne, J., de Lavallade, H., Osborne, W., Robinson, L., et al. (2019) · The Lancet Haematology

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 195

Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression

Lucas, C. M., Harris, R. J., Giannoudis, A., Copland, M., Slupsky, J. R., & Clark, R. E. (2011) · Blood

Chronic Myeloid Leukemia TreatmentsProtein Tyrosine Phosphatases

Cited by 138

Longitudinal dynamics of clonal hematopoiesis identifies gene-specific fitness effects

Robertson, N. A., Latorre-Crespo, E., Terradas-Terradas, M., Lemos-Portela, J., Purcell, A. C., Livesey, B. J., Hillary, R. F., Murphy, L., Fawkes, A., MacGillivray, L., et al. (2022) · Nature Medicine

Acute Myeloid Leukemia ResearchCancer Genomics and Diagnostics

Cited by 132

CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy

Kinstrie, R., Horne, G. A., Morrison, H., Irvine, D., Munje, C., Castañeda, E. G., Moka, H. A., Dunn, K., Cassels, J. E., Parry, N., et al. (2020) · Leukemia

Chronic Myeloid Leukemia TreatmentsAcute Myeloid Leukemia Research

Cited by 67

Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression

Clark, R. E., Apperley, J. F., Copland, M., & Cicconi, S. (2021) · Blood Advances

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 53

Expectations and outcomes of varying treatment strategies for CML presenting during pregnancy

Robertson, H. F., Milojkovic, D., Butt, N., Byrne, J., Claudiani, S., Copland, M., Gallipoli, P., Innes, A. J., Knight, K., Mahdi, A. J., et al. (2024) · British Journal of Haematology

Chronic Myeloid Leukemia TreatmentsPregnancy and Medication Impact

Cited by 13

Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy

Innes, A. J., Hayden, C., Orovboni, V., Claudiani, S., Fernando, F., Khan, A., Rees, D., Byrne, J., Gallipoli, P., Francis, S., et al. (2024) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 13